API
< Back to all clusters
[HEALTH] · 2 sources

started · updated

GLP-1 receptor agonists studied for autoimmune and lower extremity effects

Recent medical reviews and studies are examining the clinical implications of glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, which are widely used for diabetes and obesity.

In podiatric medicine, observational studies suggest a potential association between GLP-1RA use and a reduction in diabetic foot ulcers and lower extremity amputations, though a causal preventative link has not been established. Research is ongoing regarding their impact on wound healing and peripheral neuropathy.

A comparative study using electronic health records evaluated the immunologic safety of GLP-1RAs against other diabetes medications, including DPP-4 inhibitors (DPP-4i) and SGLT2 inhibitors (SGLT2i). The findings indicated that while DPP-4i use was associated with a lower risk of psoriasis and autoimmune thyroiditis compared to GLP-1RAs, it also showed a higher risk for conditions such as dermatomyositis and bullous pemphigoid. No significant differences in autoimmune disease risk were observed between GLP-1RAs and SGLT2i treatments.

Entities

GLP-1 receptor agonists · TriNetX

Sources

GLP-1 Receptor Agonists and the Lower Extremity [www.hmpgloballearningnetwork.com]